title: Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.
abstract: Peroxiredoxins (Prdxs) are a family of antioxidant enzymes that are also known as scavengers of peroxide in mammalian cells. Some reports have shown that the overexpression of Prdx1, which is one of the peroxiredoxins that is a ubiquitously expressed protein, was related to a poor prognosis in several types of human cancers. In this study, we investigated the expression levels of Prdx1 in esophageal squamous cell carcinoma by immunohistochemistry, and the correlation between the Prdx1 expression and the clinical status was elucidated. Immunohistochemical staining was performed in 114 samples which were collected from surgical esophageal cancer specimens. Cytoplasmic staining of Prdx1 was evaluated based on the following scoring criteria: Grade I, negative or weak staining; Grade II, moderate staining; and Grade III, strong staining. The percentage of patients with a Grade I expression of Prx1 was 20% (23 of 114), 44% had Grade II (50 of 114), and 36% had Grade III (41 of 114). The Prdx1 immunoreactivity showed an inverse significant correlation with T-category (P<0.0001), lymph node metastasis (P=0.048), and stage (P=0.001). In addition, the patients with tumors exhibiting a reduced Prdx1 expression had shorter overall survival (P=0.022) in comparison to the patients with tumors which had a higher Prdx1 expression. Currently, Prdx1 has been shown to act as a tumor suppressor. Our results provide strong evidence that the reduced Prdx1 expression is an important factor in esophageal squamous cancer progression and could serve as a useful prognostic marker.
authors.affiliation: Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
authors.forename: Isamu
authors.initials: I
authors.lastname: Hoshino
authors.forename: Hisahiro
authors.initials: H
authors.lastname: Matsubara
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Akutsu
authors.forename: Takanori
authors.initials: T
authors.lastname: Nishimori
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoneyama
authors.forename: Kentaro
authors.initials: K
authors.lastname: Murakami
authors.forename: Haruhito
authors.initials: H
authors.lastname: Sakata
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Matsushita
authors.forename: Takenori
authors.initials: T
authors.lastname: Ochiai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000556:secondary; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D054464:Peroxiredoxins / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate